中国药物警戒 ›› 2026, Vol. 23 ›› Issue (5): 575-577.
DOI: 10.19803/j.1672-8629.20250724

• 安全与合理用药 • 上一篇    下一篇

硫普罗宁肠溶胶囊致粒细胞缺乏症1例分析

戴彪1,2,3,4, 张松1,2,3,4, 邓逸芸1,2,3,4, 曹银1,2,3,4, 张元元1,2,3,4, 李培培1,2,3,4, 梁俊1,2,3,4,*   

  1. 1安徽医科大学附属心理医院药剂科,安徽 合肥 230022;
    2合肥市第四人民医院药剂科,安徽 合肥 230022;
    3安徽省精神卫生中心精神药理研究室,安徽 合肥 230022;
    4安徽省精神心理疾病临床医学研究中心,安徽 合肥 230022
  • 收稿日期:2025-10-17 发布日期:2026-05-20
  • 通讯作者: *梁俊,女,硕士,主任药师,临床药学。E-mail: 1309071273@qq.com
  • 作者简介:戴彪,男,硕士,副主任药师,临床药学。
  • 基金资助:
    国家自然科学基金资助项目（82304847）; 国家临床重点专科项目资助; 安徽省临床重点专科项目资助; 合肥市第七周期重点（培育）专科资助

One Case of Agranulocytosis Caused by Tiopronin Enteric-Coated Capsules

DAI Biao1,2,3,4, ZHANG Song1,2,3,4, DENG Yiyun1,2,3,4, CAO Yin1,2,3,4, ZHANG Yuanyuan1,2,3,4, LI Peipei1,2,3,4, LIANG Jun1,2,3,4,*   

  1. 1Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei Anhui 230022, China;
    2Department of Pharmacy, Hefei Fourth People's Hospital, Hefei Anhui 230022, China;
    3Psychopharmacology Research Laboratory, Anhui Provincial Mental Health Center, Hefei Anhui 230022, China;
    4Clinical Medical Research Center of Mental and Psychological Diseases in Anhui Province, Hefei Anhui 230022, China
  • Received:2025-10-17 Published:2026-05-20

PDF (PC)

26

摘要： 目的 探讨硫普罗宁肠溶胶囊致粒细胞缺乏症的不良反应,为临床安全用药提供参考。方法 对1例精神分裂症患者应用硫普罗宁肠溶胶囊治疗肝损伤诱发粒细胞缺乏症病历进行分析,并对相关文献进行归纳和总结。结果 患者使用帕利哌酮缓释片出现肝损伤,应用硫普罗宁肠溶胶囊0.6 g·d-1保肝治疗8 d后出现持续发热,血常规示粒细胞缺乏症。予以停药、抗感染、人粒细胞集落刺激因子和地榆升白胶囊对症支持治疗后粒细胞恢复正常。结论 硫普罗宁肠溶胶囊治疗过程中需关注可能诱发的血液系统毒性。联合抗精神病药物治疗时,应重点关注患者临床表现和血常规结果。

关键词: 硫普罗宁, 白细胞减少, 粒细胞缺乏症, 帕利哌酮, 药品不良反应

Abstract: Objective To investigate the adverse drug reaction of agranulocytosis caused by tiopronin enteric-coated capsules and provide a reference for safe medication in clinical practice. Methods One case of agranulocytosis induced by tiopronin enteric-coated capsules in a schizophrenia patient with liver injury was analyzed. Related literature was also reviewed and summarized. Results The patient developed liver injury after treatment with paliperidone extended-release tablets. Agranulocytosis accompanied by persistent fever occurred 8 days after combination therapy with tiopronin enteric-coated capsules (0.6 g·d⁻¹) for hepatoprotection. The granulocyte count returned to normal after discontinuation of the suspected drug and symptomatic treatment with anti-infectives, the human granulocyte colony-stimulating factor, and Diyu Shengbai capsules. Conclusion Potential hematologic toxicity, such as agranulocytosis, deserves attention during treatment with tiopronin enteric-coated capsules. When tiopronin is combined with antipsychotics, special attention should be paid to the patient's clinical manifestations and blood routine results.

Key words: Tiopronin, Leukopenia, Agranulocytosis, Paliperidone, Adverse Drug Reaction

中图分类号: